Biogen Inc   (BIIB)
Other Ticker:  
Price: $308.8800 $3.98 1.305%
Day's High: $311.28 Week Perf: 2.89 %
Day's Low: $ 303.69 30 Day Perf: -1.63 %
Volume (M): 1,232 52 Wk High: $ 319.74
Volume (M$): $ 380,633 52 Wk Avg: $262.01
Open: $310.69 52 Wk Low: $188.54

 Market Capitalization (Millions $) 44,849
 Shares Outstanding (Millions) 145
 Employees 9,610
 Revenues (TTM) (Millions $) 10,105
 Net Income (TTM) (Millions $) 3,131
 Cash Flow (TTM) (Millions $) -541
 Capital Exp. (TTM) (Millions $) 227

Biogen Inc
Biogen Idec creates new standards of care in oncology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, we transform scientific discoveries into advances in human healthcare. We currently have four commercial products: AVONEX' (Interferon beta-1a) for the treatment of relapsing multiple sclerosis, also known as MS, RITUXAN' (rituximab)'and ZEVALIN' (ibritumomab tiuxetan), both of which treat certain B-cell non-Hodgkin's lymphomas, also referred to as B-cell NHLs, and AMEVIVE' (alefacept)'for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Our sales and marketing efforts are generally focused on specialist physicians in private practice or at major medical centers. We utilize common pharmaceutical company practices to market our products and to educate physicians, including sales representatives calling on individual physicians and distributors, advertisements, professional symposia, direct mail, selling initiatives, public relations and other methods. We have also established uninsured patient programs in the U.S.' for our marketed products which provide qualified patients with products at no charge. We also provide certain customer service and other related programs for our products, such as disease and product-specific websites, insurance verification services and order, delivery and fulfillment services.

Competition in the biotechnology and pharmaceutical industries is intense and comes from many and varied sources. We do not believe that any of the industry leaders can be considered dominant in view of the rapid technological change in the industry. We experience significant competition from specialized biotechnology firms in the U.S., the EU and elsewhere and from many large pharmaceutical, chemical and other companies.


AVONEX competed in the U.S. and EU markets primarily with three products:

''BETASERON', sold by Berlex in the U.S. and sold under the name BETAFERON' by Schering A.G.

''REBIF', which is co-promoted by Serono, Inc. and Pfizer in the U.S. and sold by Serono AG in the EU.

''COPAXONE' glatiramer acetate, sold by Teva Neuroscience, Inc. in the U.S. and co-promoted by Teva and Aventis Pharma in the EU.

RITUXAN is typically used after patients fail to respond or relapse after treatment with traditional radiation therapy or standard chemotherapy regimes, such as CVP and CHOP. ZEVALIN is typically used after patients fail to respond or relapse following treatment with RITUXAN. ZEVALIN competes with BEXXAR' (tositumomab, iodine I-131 tositumomab), a radiolabeled molecule developed by Corixa Corporation and GlaxoSmithKline. BEXXAR received FDA approval in June 2003 to treat patients with CD20+, follicular, NHL, with and without transformation, whose disease is refractory to RITUXAN and has relapsed following chemotherapy.


AMEVIVE competes with several different types of therapies including:

''traditional therapies for moderate-to-severe chronic plaque psoriasis, such as oral retinoids, steroids, methotrexate, cyclosporin, PUVA and UVB radiation.

''RAPTIVA' (efalizumab), a drug co-developed by Genentech and Xoma Corporation that was approved by the FDA in November 2003 to treat moderate-to-severe psoriasis. Serono has an exclusive license to RAPTIVA in the EU and other countries and has filed for regulatory approval of the drug in the EU. Drugs approved for other indications that are used to treat psoriasis. Among these drugs are ENBREL' (etanercept), REMICADE' (infliximab)'and HUMIRA'(adalimumab). ENBREL is sold by Amgen, Inc. and Wyeth Pharmaceuticals, Inc. and is approved to treat psoriatic arthritis. In January 2003, Amgen announced positive results from a Phase'3 clinical study of ENBREL in the treatment of moderate-to-severe plaque psoriasis and is conducting a second Phase'3 clinical study in psoriasis. REMICADE is sold worldwide by Centocor, Inc., a subsidiary of Johnson'& Johnson, as a treatment for other indications, including rheumatoid arthritis, and is currently in a Phase'2 proof of concept study as a potential treatment for psoriasis. HUMIRA is sold by Abbott Laboratories and is approved to treat rheumatoid arthritis. Abbott is undertaking clinical trials in psoriasis and psoriatic arthritis.

   Company Address: 225 Binney Street Cambridge 2142 MA
   Company Phone Number: 679-2000   Stock Exchange / Ticker: NASDAQ BIIB
   BIIB is expected to report next financial results on July 19, 2023.

Customers Net Income grew by BIIB's Customers Net Profit Margin fell to

8.68 %

4.26 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
AMGN        0.32% 
ABBV        0.96% 
ABT   -2.41%    
BMY   -1.31%    
JNJ        1.94% 
PFE        1.59% 
• View Complete Report

Lakeland Industries Inc

Earnings Jumped by 28.57 % at the Lakeland Industries Inc in the first quarter of 2024

Investors, rejoice! The stock market has shown promising growth with Lakeland Industries Inc announcing impressive earnings for the first quarter of 2024. The company's earnings per share have advanced by 28.57% to $0.18 per share compared to $0.14 per share from the previous year, and notably, it has even surpassed its earnings of $0.00 per share from the prior reporting season.
Moreover, Lakeland Industries Inc has reported revenue growth by 5.213% from $27.28 million to $28.70 million from the similar reporting season a year before. Though sequentially, revenue fell by -16.901% from $34.54 million, the company has continued to thrive and has reported net profits of $1.320 million, which is a growth of 16.92% from its net earnings of $1.129 million in the first quarter of 2024 a year ago.

Agilent Technologies Inc

Reasonable result at Agilent Technologies Inc over the financial second quarter of 2023

Agilent Technologies Inc, a Biotechnology and Pharmaceuticals company has released its financial results for the three months ending April 30, 2023. The company's revenue increased by 6.845% to $1.72 billion as compared to $1.61 billion on a year-over-year basis. Meanwhile, the company's profitability showed significant improvement, with profits rising 12.09% to $1.02 from $0.91 in the prior year reporting season.
However, there was a decrease in revenue by -2.221% from $1.76 billion in the preceding period, and profits also fell by -14.29% from $1.19 per share. Despite these reductions, earnings rose by 10.22% from net earnings of $274.000 million reported in the second quarter of the 2023 earnings season a year ago.

Steris Plc

The Biotechnology and Pharmaceuticals company has failed to turn into profitability despite the epic Surge in revenue in the fourth quarter of 2023

Steris Plc, a leading biotechnology and pharmaceuticals company, has announced a significant increase in revenue for the most recent fiscal period. The company reported a year-on-year revenue rise of 311.172% to $2.94 billion, which is an impressive figure. However, the company slipped into a net loss of $-0.60. This news is significant and has caused some concern among investors and stakeholders.
Compared to the preceding quarter, the income per share fell from $0.56 per share. On the other hand, revenue doubled by a substantial 322.827% from $696.24 million. In the fourth quarter of 2023, Steris Plc posted a net loss of $-90.386 million, as opposed to the net proceeds of $73.623 million recorded in the same quarter a year before. This decline in profits is concerning and indicates a downward trend.

Burzynski Research Institute Inc

The emerging corporation from the Biotechnology and Pharmaceuticals market the Burzynski Research Institute Inc issued the fourth quarter of 2023, results

As a journalist who closely follows the financial performance of various corporations, I find the latest results from Burzynski Research Institute Inc quite intriguing. This small biotech and pharmaceutical firm has reported an operating deficit of $-0.215998 million for the fourth quarter of 2023. While the company has not yet revealed its revenue figures, it is worth comparing these results with the corresponding period from the previous year.
In the fourth quarter of 2022, Burzynski Research Institute Inc had already reported an operating deficit of $-0.131272 million. The fact that the shortfall has further expanded to $-0.216 million in the same quarter of 2023 suggests that the company is going through a turbulent period. However, it's important to note that many businesses face such choppy phases while they try to establish prosperous revenue sources.

Immunovant Inc

The Biotechnology and Pharmaceuticals company announced Revenue of $4.098 million, in the financial fourth quarter of 2023

Immunovant Inc, a clinical stage biopharmaceutical company, has reported their financial results for the fiscal period ending March 31, 2023. According to the report, the company generated revenue of $4.098 million, which is a positive sign.
However, the company also reported a net loss of $59.432 million for the same period, higher than the previous year's loss of $47.171 million. The net loss per share has worsened from $1.43 in the previous fiscal year to $1.71 in this fiscal year, indicating that the company is facing some financial challenges.


Biogen Inc's Segments
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Biogen Inc announced annual revenue outlook on

Earnings Outlook
Biogen Inc issued annual earnings guidance on

Geographic Revenue Dispersion
United States


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071